Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease | Zendy

Ran Reshef | Zendy; Selina M. Luger | Zendy; Elizabeth O. Hexner | Zendy; Alison W. Loren | Zendy; Noelle V. Frey | Zendy; Sunita D. Nasta | Zendy; Steven C. Goldstein | Zendy; Edward A. Stadtmauer | Zendy; Jacqueline Smith | Zendy; S. Bailey | Zendy; Rosemarie Mick | Zendy; Daniel F. Heitjan | Zendy; Stephen G. Emerson | Zendy; James A. Hoxie | Zendy; Robert H. Vonderheide | Zendy; David Porter | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

Author(s) -

Ran Reshef,

Selina M. Luger,

Elizabeth O. Hexner,

Alison W. Loren,

Noelle V. Frey,

Sunita D. Nasta,

Steven C. Goldstein,

Edward A. Stadtmauer,

Jacqueline Smith,

S. Bailey,

Rosemarie Mick,

Daniel F. Heitjan,

Stephen G. Emerson,

James A. Hoxie,

Robert H. Vonderheide,

David Porter

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1201248

Subject(s) - maraviroc , ccr5 receptor antagonist , medicine , immunology , hematopoietic stem cell transplantation , graft versus host disease , cumulative incidence , transplantation , lymphocyte , chemokine , chemokine receptor ccr5 , chemokine receptor , immune system , human immunodeficiency virus (hiv)

Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic hematopoietic stem-cell transplantation (HSCT). The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research